Figshare · Jun 6, 2026

An Ecological Analysis of Menopausal Hormone Restoration

By Catherino D

Ecological medicine views the body as an integrated system rather than a collection of organ-specific risk profiles. In women’s health, it treats estrogen and progesterone as systemic hormones with regulatory roles across the cardiovascular, skeletal, bone marrow, neurocognitive, genitourinary, metabolic and immune signaling systems, and it comprehensively evaluates interventions by the long-term consequences of hormonal deprivation versus restoration.An ecological women's health oriented analysis of the menopause hormone therapy literature suggests that the central error of the past two decades rests on a reductive framework which conceptualizes menopausal hormone deficiency as a neutral baseline and treats breast cancer incidence as if it were a validated proxy for breast cancer mortality.Within an ecological framework, Women's Health Initiative (WHI) findings become less paradoxical and more clarifying. At 20-year followup, conjugated equine estrogen (CEE) alone was associated with lower breast cancer incidence and lower breast cancer mortality, while CEE plus medroxyprogesterone acetate (MPA) increased incidence without a statistically significant increase in breast cancer mortality.This pattern matters because it challenges the evidentiary logic used to restrict access to menopause hormone therapy (MHT) and physiologic dosing in older women, and to frame decades of estrogen and progesterone deficiency as a safer therapeutic practice than hormone restoration. Essentially, menopause is being managed through an anatomically reductive paradigm that isolates organ-specific risk signals while neglecting the systemic harms of prolonged endocrine deprivation, including disruption of the bone marrow microenvironment.This raises a deeper structural question about medical institutions. The restriction of physiologic hormone restoration in menopause represents a therapeutic anomaly with no equivalent in other endocrine insufficiency conditions. It is an anomaly whose persistence is difficult to reconcile on biological or evidentiary grounds.Additional context:Recent advances in bone marrow biology have materially strengthened the framework developed in this article. Single-cell and spatial transcriptomic studies increasingly support the view that the marrow is organized not as discrete endosteal and vascular niches, but as a continuous LepR⁺ (Leptin receptor positive) mesenchymal stromal network extending from the bone surface to the sinusoid. Within this architecture, LepR⁺ cells are a major source of CXCL12 and SCF signals that sustain hematopoietic stem and progenitor cell maintenance, while recent work has identified CXCL14 as an additional LepR⁺-derived perisinusoidal mediator that promotes megakaryocyte maturation and thrombopoiesis. These findings support the view that estrogen-responsive marrow function reflects coordinated outputs of a single integrated tissue system. This perspective also sharpens the clinical significance of estrogen deficiency. Contemporary reviews describe postmenopausal marrow as undergoing immune reprogramming, including myeloid skewing, adipogenic drift of mesenchymal precursors, inflammasome activation, and chronic low-grade inflammation. Osteoimmunology literature further supports the concept that estrogen deficiency may create a marrow milieu permissive to tumor cell survival and dormancy. Taken together, these findings suggest that menopausal estrogen loss reorganizes the hematopoietic-immune-stromal environment rather than simply accelerating bone resorption, with implications for blood cell production, immune surveillance, and marrow-based tumor biology.NOTE: On October 16, 2025, the Endocrine Society retired its 2015 clinical practice guideline on menopause and menopausal hormone therapy (MHT) and endorsed the European Society of Endocrinology’s 2025 menopause guideline. The new guideline preserves the same core MHT framework and restrictions: individualized use, MHT for vasomotor symptoms, avoidance of chronic disease prevention, caution in breast cancer, and a preference for transdermal estrogen in many cases. As a result, the reductive paradigm remains intact, but the Endocrine Society is no longer the direct author of the active recommendations. This makes it harder to attribute the framework to the organization whose mandate most clearly includes menopause as an endocrine condition, and defers direct responsibility for reform, since it now endorses rather than authors the MHT guideline. This is an anomaly among the Endocrine Society’s published clinical practice guidelines: menopause is the only endocrine condition in which the Society retired its own guideline and deferred to another society’s guideline rather than publishing a parallel update. For all other endocrine disorders where it issues guidelines, it continues to produce and maintain its own guidelines.

doi.org/10.6084/m9.figshare.32594601Open accessInterventions